Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-03-07
2006-03-07
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S009100, C424S009200, C424S184100, C424S185100, C424S190100, C424S234100, C530S300000, C530S350000
Reexamination Certificate
active
07008625
ABSTRACT:
Novel chimeric nucleic acids, encoding chimericBorreliaproteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.
REFERENCES:
patent: 5217872 (1993-06-01), Dorward et al.
patent: 5470712 (1995-11-01), Simpson et al.
patent: 5523089 (1996-06-01), Bergstrom et al.
patent: 5571718 (1996-11-01), Dunn et al.
patent: 5620862 (1997-04-01), Padula
patent: 5688512 (1997-11-01), Bergstrom et al.
patent: 5747294 (1998-05-01), Flavell et al.
patent: 5777095 (1998-07-01), Barbour et al.
patent: 5780041 (1998-07-01), Simpson et al.
patent: 6113914 (2000-09-01), Lobet et al.
patent: 6197301 (2001-03-01), Flavell et al.
patent: 6210676 (2001-04-01), Callister et al.
patent: 6248562 (2001-06-01), Dunn et al.
patent: 2004/0023325 (2004-02-01), Luft et al.
patent: 0 418 827 (1991-03-01), None
patent: 0 465 204 (1992-01-01), None
patent: 0 492 964 (1992-07-01), None
patent: 0 522 560 (1993-01-01), None
patent: 0 540 457 (1993-05-01), None
patent: 0 711 563 (1996-05-01), None
patent: 0 643 974 (1999-01-01), None
patent: 0 598 816 (1999-06-01), None
patent: 1 016 416 (2000-05-01), None
patent: WO 90/04411 (1990-05-01), None
patent: WO 91/09870 (1991-07-01), None
patent: WO 91/13630 (1991-09-01), None
patent: WO 93/04175 (1993-03-01), None
patent: WO 93/08286 (1993-04-01), None
patent: WO 93/08299 (1993-04-01), None
patent: WO 93/08306 (1993-04-01), None
patent: WO 93/10237 (1993-05-01), None
patent: WO 94/19697 (1994-09-01), None
patent: WO 94/20536 (1994-09-01), None
patent: WO 94/25596 (1994-11-01), None
patent: WO 95/12676 (1995-05-01), None
patent: WO 96/40290 (1996-12-01), None
patent: WO 96/40718 (1996-12-01), None
patent: WO 97/42221 (1997-11-01), None
patent: WO 92/00055 (1999-01-01), None
patent: WO 99/14345 (1999-03-01), None
patent: WO 00/06745 (2000-02-01), None
Kumaran D., et al. “Crystal Structure of Outer Surface Protein C (OspC) From the Lyme Disease Spirochete,Borrelia burgdorferi,”EMBO J. 20(5):971-978 (2001).
Li, H., et al., “Crystal Structure of Lyme Disease Antigen Outer Surface Protein A Complexed With An Fab,”Proc. Natl. Acad. Sci. USA, 94:3584-3589 (1997).
Barbour, A.G., et al., “Lyme Disease Spirochetes and Ixodid Tick Spirochetes Share a Common Surface Antigenic Determinant Defined by a Monoclonal Antibody,”Infect. Immun. 41(2):795-804 (1983).
Wallich, R. et al., “DNA Vaccines Expressing a Fusion Products of Outer Surface Proteins A and C fromBorrelia burgdorferiInduce Protective Antibodies Suitable for Prophylaxis but Not for Resolution of Lyme Disease,”Infect. Immun., 69(4):2130-2136 (2001).
Kalish, R.S., et al., “Lyme Disease: Human T-cell Response to OspA and OspC Borrelia Lipoproteins Includes Both CD8+ and CD4+ T-Cells,”J. Invest. Dermatol., 114(4):836 Abstract 523 (2000).
Luft, B.J., et al., “A New Multi-Target OspA-OspC Vaccine for Lyme Disease,”Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 40:248 Abstract 1932 (2000).
Gomes-Solecki, M.J.C., et al., “Recombinant Chimeric Borrelia Proteins for Diagnosis of Lyme Disease,”J. Clin. Microbiol., 38(7):2530-2535 (2000).
Bakken, L.L., et al., “Interlaboratory Comparison of Test Results for Detection of Lyme Disease by 516 Participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program,”J. Clin. Microbiol., 35(3):537-543 (1997).
Chang, Y-F., et al., “Expression and Secretion of Outer Surface Protein (OSP-A) ofBorrelia burgdorferiFromEscherichia coli,”FEMS Microbiol. Lett.109:297-301 (1993).
De, B.K., et al., “Purification and Characterization ofStreptococcus pneumoniaePalmitoylated pneumococcal surface adhesin A expressed inEscherichia coli,”Vaccine, 18:1811-1821 (2000).
de Silva, A.M., et al., “Borrelia burgdorferiOspA Is an Arthropod-Specific Transmission-Blocking Lyme Disease Vaccine,”J. Exp. Med.183(1):271-275 (1996).
de Silva, A.M. and E. Fikrig, “Arthopod- and Host-Specific Gene Expression byBorrelia burgdorferi,”J. Clin. Invest.99(3):377-379 (1997).
Fingerle, V., et al., “Expression of Outer Surface Proteins A and C ofBorrelia burgdorferiinIxodes ricinusTicks Removed from Humans,”Med. Microbiol. Immunol.187(2):121-126 (1998).
Dykhuizen, D.E., et al., “Borrelia burgdorferiis Clonal: Implications for Taxonomy and Vaccine Development,”Proc. Natl. Acad. Sci. USA90:10163-10167 (1993).
Gilmore, R.D., Jr., et al., “Outer Surface Protein C (OspC), but Not P39, Is a Protective Immunogen Against a Tick-TransmittedBorrelia burgdorferiChallenge: Evidence for a Conformational Protective Epitope in OspC,”Infect. Immun.(64)6:2234-2239 (1996).
Montgomery, R.R., et al., “Direct Demonstration of Antigenic Substitution ofBorrelia burgdorferiEx Vivo: Exploration of the Paradox of the Early Immune Response to Outer Surface Proteins A and C in Lyme Disease,”J. Exp. Med.183 (1):261-269 (1996).
Probert, W.S. and R.B. LeFebvre, “Protections of C3H/HeN Mice from Challenge withBorrelia burgdorferithrough Active Immunization with OspA, OspB, or OspC, but Not OspD or the 83-Kilodalton Antigen,”Infect. Immun.62(5):1920-1926 (1994).
Probert, W.S., et al., “Immunization with Outer Surface Protein (Osp) A, but Not OspC, Provides Cross-Protection of Mice Challenged with North American Isolates ofBorrelia burgdorferi,”J. Infect. Dis.175(2):400-405 (1997).
Schwan, T.G., et al., “Induction of an Outer Surface Protein onBorrelia burgdorferiDuring Tick-Feeding,”Proc. Natl. Acad. Sci. USA92:2909-2913 (1995).
Simon, M.M., et al., “Protective Immunization with Plasmid DNA Containing the Outer Surface Lipoprotein A Gene ofBorrelia burgdorferiis Independent of an Eukaryotic Promoter,”Eur. J. Immunol.26(12):2831-2840 (1996).
Simon, M.M., et al., “Lyme Disease: Pathogenesis and Vaccine Development,”Zent.bl. Bakteriol.289:690-695 (1999).
Solé, M., et al., “Borrelia burgdorferiEscape Mutants That Survive in the Presence of Antiserum to the OspA Vaccine Are Killed When Complement Is Also Present,”Infect. Immun.66(6):2540-2546 (1998).
Steigbigel, R.T. and J.L. Benach, “Immunization Against Lyme Disease-An Important First Step,”N. Engl. J. Med.339(4):263-264 (1998).
Stover, C.K., et al., “Protective Immunity Elicited by rBCG Vaccines,”Dev. Biol. Stand.82:163-170 (1994).
Thanassi, W.T. and R.T. Schoen, “The Lyme Disease Vaccine: Conception, Development, and Implementation,”Ann. Intern. Med.132:661-668 (2000).
Wahlberg, P., “Vaccination Against Lyme borreliosis,”Ann. Med.31:233-235 (1999).
Wang, I-N., et al., “Genetic Diversity of ospC in a Local Population ofBorrelia burgdorferi sensu stricto,”Genetics151:15-30 (1999).
Wieneke, C.A., et al., “Evaluation of Whole-Cell and OspC Enzyme-Linked Immunosorbent Assays for Discrimination of Early Lyme Borreliosis from OspA Vaccination,”J. Clin. Microbiol.,38(1):313-317 (2000).
Wilske, B., et al., “Diversity of OspA and OspC among Cerebrospinal Fluid Ioslates ofBorrelia burgdorferisensu lato from Patients with Neuroborreliosis in Germany,”Med. Microbiol. Immunol.184:195-201 (1996).
Wilske, B., et al., “Immunological and Molecular Variability of OspA and OspC. Implications ofBorreliaVaccine Development,”Infection24(2):208-212 (1996).
Wilske, B., et al., “Immunological and Molecular Polymorphisms of OspC, an Immunodominant Major Outer Surface Protein ofBorrelia burgdorferi,”Infect. Immun.61(5):2182-2191 (1993).
Zhong, W. et al., “Therapeutic Passive Vaccination Against Chronic Lyme Disease in Mice,”Proc. Natl. Acad. Sci. USA94:12533-12538 (199
Dattwyler Raymond J.
Dunn John J.
Gomes-Solecki Maria J. C.
Luft Benjamin J.
Hamilton Brook Smith & Reynolds P.C.
Research Foundation of the State University of New York
Swartz Rodney P.
LandOfFree
Recombinant constructs of Borrelia burgdorferi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant constructs of Borrelia burgdorferi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant constructs of Borrelia burgdorferi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548338